SI3497132T1 - Režimi in postopki zdravljenja multiple skleroze z uporabo ofatumumaba - Google Patents
Režimi in postopki zdravljenja multiple skleroze z uporabo ofatumumabaInfo
- Publication number
- SI3497132T1 SI3497132T1 SI201730400T SI201730400T SI3497132T1 SI 3497132 T1 SI3497132 T1 SI 3497132T1 SI 201730400 T SI201730400 T SI 201730400T SI 201730400 T SI201730400 T SI 201730400T SI 3497132 T1 SI3497132 T1 SI 3497132T1
- Authority
- SI
- Slovenia
- Prior art keywords
- ofatumumab
- regimens
- methods
- multiple sclerosis
- treating multiple
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Pressure Welding/Diffusion-Bonding (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374986P | 2016-08-15 | 2016-08-15 | |
| EP17768863.7A EP3497132B1 (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
| PCT/IB2017/054909 WO2018033841A1 (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3497132T1 true SI3497132T1 (sl) | 2020-10-30 |
Family
ID=59901554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201730400T SI3497132T1 (sl) | 2016-08-15 | 2017-08-11 | Režimi in postopki zdravljenja multiple skleroze z uporabo ofatumumaba |
| SI201731396T SI3733712T1 (sl) | 2016-08-15 | 2017-08-11 | Režimi in postopki zdravljenja multiple skleroze z uporabo ofatumumaba |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201731396T SI3733712T1 (sl) | 2016-08-15 | 2017-08-11 | Režimi in postopki zdravljenja multiple skleroze z uporabo ofatumumaba |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US11161909B2 (enExample) |
| EP (4) | EP3497132B1 (enExample) |
| JP (2) | JP6851391B2 (enExample) |
| KR (2) | KR20200136503A (enExample) |
| CN (5) | CN120053638A (enExample) |
| AU (2) | AU2017311664C1 (enExample) |
| CA (2) | CA3101514A1 (enExample) |
| CY (1) | CY1123350T1 (enExample) |
| DE (1) | DE202017007542U1 (enExample) |
| DK (2) | DK3733712T3 (enExample) |
| ES (2) | ES2821924T3 (enExample) |
| FI (1) | FI3733712T3 (enExample) |
| HR (2) | HRP20201388T1 (enExample) |
| HU (2) | HUE063625T2 (enExample) |
| IL (4) | IL302488B2 (enExample) |
| LT (2) | LT3733712T (enExample) |
| MX (1) | MX388593B (enExample) |
| PL (2) | PL3733712T3 (enExample) |
| PT (2) | PT3497132T (enExample) |
| RS (2) | RS64541B1 (enExample) |
| RU (1) | RU2749951C2 (enExample) |
| SI (2) | SI3497132T1 (enExample) |
| TW (1) | TWI752995B (enExample) |
| WO (1) | WO2018033841A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3101514A1 (en) * | 2016-08-15 | 2018-02-22 | Novartis Ag | Regimens and methods of treating multiple sclerosis using ofatumumab |
| EP4028421A1 (en) * | 2019-09-11 | 2022-07-20 | Novartis AG | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| MX2022003010A (es) | 2019-09-11 | 2022-06-02 | Novartis Ag | Tratamiento de la emr mediante cambio de terapia. |
| US20230151106A1 (en) * | 2020-04-09 | 2023-05-18 | Novartis Ag | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG |
| EP4323000A1 (en) * | 2021-04-14 | 2024-02-21 | Novartis AG | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4816401A (en) | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| JP2003529361A (ja) | 2000-03-30 | 2003-10-07 | アムジェン インコーポレイテッド | ＣＤ２０／ＩｇＥレセプター様分子およびその使用 |
| EA007958B1 (ru) | 2000-08-03 | 2007-02-27 | Терапеутик Хьюман Поликлоналз Инк. | ТРАНСГЕННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ГУМАНИЗИРОВАННЫЙ ЛОКУС Ig, И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТРАНСГЕННЫХ ЖИВОТНЫХ |
| ES2744275T3 (es) | 2002-10-17 | 2020-02-24 | Genmab As | Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| AR082436A1 (es) | 2010-08-02 | 2012-12-05 | Sanofi Aventis Us Llc | Uso de teriflunomida para tratar la esclerosis multiple |
| JP2014506258A (ja) * | 2011-01-10 | 2014-03-13 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 新規使用 |
| AU2013200903B2 (en) * | 2012-02-08 | 2015-05-14 | Mcure Biosciences Inc. | CDIM binding proteins and uses thereof |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| AU2013299557B2 (en) | 2012-08-10 | 2017-06-22 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors |
| WO2015162504A1 (en) | 2014-04-23 | 2015-10-29 | Novartis Ag | Novel dosing and uses of ofatumumab |
| JP2017514824A (ja) | 2014-04-29 | 2017-06-08 | テバ ファーマシューティカル インダストリーズ リミティド | 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド |
| CN107407677B (zh) | 2015-01-28 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 多发性硬化的基因表达标志和治疗 |
| CN106699886A (zh) | 2015-07-13 | 2017-05-24 | 西藏海思科药业集团股份有限公司 | 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体 |
| CA3101514A1 (en) | 2016-08-15 | 2018-02-22 | Novartis Ag | Regimens and methods of treating multiple sclerosis using ofatumumab |
| MX2022003010A (es) | 2019-09-11 | 2022-06-02 | Novartis Ag | Tratamiento de la emr mediante cambio de terapia. |
| EP4028421A1 (en) | 2019-09-11 | 2022-07-20 | Novartis AG | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| US20230151106A1 (en) | 2020-04-09 | 2023-05-18 | Novartis Ag | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG |
| EP4323000A1 (en) | 2021-04-14 | 2024-02-21 | Novartis AG | Ofatumumab for treating multiple sclerosis in asian patients |
| IL310813A (en) | 2021-08-16 | 2024-04-01 | Novartis Ag | OFATUMUMAB for the treatment of multiple sclerosis in children |
-
2017
- 2017-08-11 CA CA3101514A patent/CA3101514A1/en active Pending
- 2017-08-11 CN CN202510270941.5A patent/CN120053638A/zh active Pending
- 2017-08-11 DK DK20180938.1T patent/DK3733712T3/da active
- 2017-08-11 HR HRP20201388TT patent/HRP20201388T1/hr unknown
- 2017-08-11 CN CN202510270924.1A patent/CN120000782A/zh active Pending
- 2017-08-11 LT LTEP20180938.1T patent/LT3733712T/lt unknown
- 2017-08-11 IL IL302488A patent/IL302488B2/en unknown
- 2017-08-11 EP EP17768863.7A patent/EP3497132B1/en active Active
- 2017-08-11 LT LTEP17768863.7T patent/LT3497132T/lt unknown
- 2017-08-11 ES ES17768863T patent/ES2821924T3/es active Active
- 2017-08-11 EP EP24166956.3A patent/EP4371611A3/en active Pending
- 2017-08-11 CN CN201780049932.7A patent/CN109641965A/zh active Pending
- 2017-08-11 DE DE202017007542.3U patent/DE202017007542U1/de active Active
- 2017-08-11 DK DK17768863.7T patent/DK3497132T3/da active
- 2017-08-11 RU RU2019107146A patent/RU2749951C2/ru active
- 2017-08-11 CN CN202510270961.2A patent/CN120053639A/zh active Pending
- 2017-08-11 HU HUE20180938A patent/HUE063625T2/hu unknown
- 2017-08-11 KR KR1020207034140A patent/KR20200136503A/ko not_active Ceased
- 2017-08-11 US US16/324,619 patent/US11161909B2/en active Active
- 2017-08-11 AU AU2017311664A patent/AU2017311664C1/en active Active
- 2017-08-11 CA CA3030530A patent/CA3030530C/en active Active
- 2017-08-11 PT PT177688637T patent/PT3497132T/pt unknown
- 2017-08-11 KR KR1020197007454A patent/KR20190038914A/ko not_active Ceased
- 2017-08-11 CN CN202510270903.XA patent/CN120037367A/zh active Pending
- 2017-08-11 PL PL20180938.1T patent/PL3733712T3/pl unknown
- 2017-08-11 SI SI201730400T patent/SI3497132T1/sl unknown
- 2017-08-11 PL PL17768863T patent/PL3497132T3/pl unknown
- 2017-08-11 RS RS20230635A patent/RS64541B1/sr unknown
- 2017-08-11 HU HUE17768863A patent/HUE051948T2/hu unknown
- 2017-08-11 RS RS20201066A patent/RS60807B1/sr unknown
- 2017-08-11 EP EP23172507.8A patent/EP4252847A3/en active Pending
- 2017-08-11 MX MX2019001860A patent/MX388593B/es unknown
- 2017-08-11 PT PT201809381T patent/PT3733712T/pt unknown
- 2017-08-11 ES ES20180938T patent/ES2954259T3/es active Active
- 2017-08-11 EP EP20180938.1A patent/EP3733712B1/en active Active
- 2017-08-11 FI FIEP20180938.1T patent/FI3733712T3/fi active
- 2017-08-11 SI SI201731396T patent/SI3733712T1/sl unknown
- 2017-08-11 IL IL313932A patent/IL313932A/en unknown
- 2017-08-11 IL IL276890A patent/IL276890B2/en unknown
- 2017-08-11 JP JP2018550539A patent/JP6851391B2/ja active Active
- 2017-08-11 WO PCT/IB2017/054909 patent/WO2018033841A1/en not_active Ceased
- 2017-08-11 HR HRP20230894TT patent/HRP20230894T1/hr unknown
- 2017-08-15 TW TW106127565A patent/TWI752995B/zh active
-
2019
- 2019-02-12 IL IL264804A patent/IL264804B/en active IP Right Grant
-
2020
- 2020-02-07 JP JP2020019337A patent/JP7198786B2/ja active Active
- 2020-02-17 AU AU2020201112A patent/AU2020201112C1/en active Active
- 2020-09-11 CY CY20201100861T patent/CY1123350T1/el unknown
-
2021
- 2021-10-06 US US17/495,559 patent/US20220081488A1/en not_active Abandoned
-
2023
- 2023-06-08 US US18/331,701 patent/US20240150485A1/en active Pending
-
2024
- 2024-03-06 US US18/597,624 patent/US12338290B2/en active Active
-
2025
- 2025-05-28 US US19/221,422 patent/US20250289902A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262416A (en) | Materials and methods for the treatment of hemoglobin diseases | |
| SG11201706767RA (en) | Materials and methods for treatment of hemoglobinopathies | |
| IL274865A (en) | Treatment methods with asparaginase | |
| IL276890A (en) | Dosing regimens and methods for the treatment of multiple sclerosis using opatumumab | |
| IL323354A (en) | Methods for treating pulmonary hypertension with combinations of relinfag and other substances | |
| IL252296A0 (en) | Methods for treating multiple sclerosis | |
| IL265359A (en) | Modified Oligonucleotides and Methods of Use | |
| IL256207B (en) | Methods for treating multiple sclerosis | |
| SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| ZA201804380B (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| SI3661510T1 (sl) | Postopki zdravljenja vedenjskih sprememb | |
| SG11201805729SA (en) | Therapeutic compositions and methods for treating hepatitis b | |
| IL259096A (en) | Peptides and methods of treating endometriosis using the same | |
| EP3134108A4 (en) | Agents and methods of treatment | |
| IL265259A (en) | Treatment of multiple sclerosis with chs-131 | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| IL265387A (en) | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan | |
| GB201621737D0 (en) | Compositions and methods of treatment | |
| GB201817198D0 (en) | Treatment ported sub and method of use | |
| ZA201906319B (en) | Methods of treating depression | |
| GB201516544D0 (en) | Spraying device and method of using same | |
| GB201605127D0 (en) | Composition and methods of treatment | |
| SG11201710199PA (en) | Methods of treating multiple sclerosis | |
| GB201710491D0 (en) | Composition and methods of treatment | |
| IL283365A (en) | Treatment methods for follicular lymphoma |